Search results for "Dosing"

showing 10 items of 128 documents

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

2019

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhib…

medicine.medical_specialtyFactor concentrate610 Medicine & healthReview Article030204 cardiovascular system & hematologyHemophilia ADrug SubstitutionHemophilia BFactor IX03 medical and health sciencesDrug substitution0302 clinical medicinePharmacokineticsmedicineDosingIntensive care medicineFactor IXClotting factorOriginal Articles: Haemostasisfactor IXFactor VIIIlcsh:RC633-647.5business.industryDosing regimenlcsh:Diseases of the blood and blood-forming organsHematology3. Good healthOnline‐only Articlesfactor VIII3121 General medicine internal medicine and other clinical medicinedrug substitution10032 Clinic for Oncology and Hematologydrug substitution; factor IX; factor VIII; hemophilia A; hemophilia Bhemophilia Bhemophilia Abusiness030215 immunologymedicine.drug
researchProduct

Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans.

2020

Abstract Objectives The inter-individual variability of warfarin dosing has been linked to genetic polymorphisms. This study was aimed at performing genotype-driven pharmacokinetic (PK) simulations to predict warfarin levels in Puerto Ricans. Methods Analysis of each individual dataset was performed by one-compartmental modeling using WinNonlin®v6.4. The k e of warfarin given a cytochrome P450 2C9 (CYP2C9) genotype ranged from 0.0189 to 0.0075 h−1. K a and V d parameters were taken from literature. Data from 128 subjects were divided into two groups (i.e., wild-types and carriers) and statistical analyses of PK parameters were performed by unpaired t-tests. Results In the carrier group (n=6…

medicine.medical_specialtyGenotypeCmax030204 cardiovascular system & hematology030226 pharmacology & pharmacyGastroenterologyArticle03 medical and health sciences0302 clinical medicinePharmacokineticsVitamin K Epoxide ReductasesInternal medicineGenotypemedicineHumansPharmacology (medical)DosingGeneral Pharmacology Toxicology and PharmaceuticsCYP2C9GenotypingCytochrome P-450 CYP2C9business.industryWarfarinArea under the curveFarmàcia InvestigacióAnticoagulantsHispanic or LatinoAryl Hydrocarbon HydroxylasesWarfarinbusinessmedicine.drugDrug metabolism and personalized therapy
researchProduct

Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

2020

Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice. Methods: Given the spectrum of medications currently available and new insights into the understanding of AI, the authors reviewed relevant medical literature with emphasis on original studies, prospective observational data and randomized controlled trials performed in the past 35 years. The Expert Opinion of a panel of selected endocrinologists was sought to answer specific clinical questions. The objective was to provide an evidence-supported guide, for the use of GC in…

medicine.medical_specialtyHydrocortisoneHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismlaw.inventionSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyGlucocorticoidRandomized controlled triallawPrednisonemedicineAdrenal insufficiencyOutpatient clinicHumansDosingIntensive care medicineGlucocorticoidsbusiness.industryAddison; Adrenal insufficiency; Cortisone acetate; Glucocorticoid; Hydrocortisone; Prednisonemedicine.diseaseItalyTransgender hormone therapyCortisone acetate030220 oncology & carcinogenesisPrednisoneObservational studybusinessMedical literaturemedicine.drugAddisonAdrenal InsufficiencyJournal of endocrinological investigation
researchProduct

Exploring gastric emptying rate in minipigs: Effect of food type and pre-dosing of metoclopramide.

2018

The present study investigated the gastric emptying rate in Gottingen minipigs pre- and post-prandial and evaluated the effect of metoclopramide on the same parameter, using paracetamol as an absorption marker. The pharmacokinetic evaluation of the obtained plasma concentration data for paracetamol demonstrated that the fastest gastric emptying rate was observed in the animals that were allowed access to normal pig food. There was no significant difference in the stomach emptying rate observed between fasted and fed minipigs, when fed either with a FDA standard breakfast or a nutritional energy drink. Pre-dosing minipigs with metoclopramide (0.2 or 0.4 mg/kg) did not demonstrate any effect …

medicine.medical_specialtyMetoclopramideMetoclopramideSwinePharmaceutical ScienceGastric emptying030226 pharmacology & pharmacyGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinemedicineAnimalsDrug InteractionsDosingAcetaminophenFood typeGastric emptyingbusiness.industrydigestive oral and skin physiologyFastingAnalgesics Non-NarcoticFasted stateStomach emptyingAcetaminophenDopamine D2 Receptor AntagonistsGastric EmptyingFood030220 oncology & carcinogenesisFed stateAntiemeticsSwine MiniatureFemalebusinessmedicine.drugFederal stateMini-pigsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.

2009

After the Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) study had demonstrated the strong vertebral and nonvertebral antifracture efficacy of daily and intermittent oral ibandronate, the Monthly Oral Ibandronate In Ladies (MOBILE) study gave evidence for an increased efficacy on the bone mineral density (BMD) of higher intermittent oral ibandronate doses (150 mg monthly) compared with 2.5 mg daily. The BONE study also observed nonvertebral antifracture efficacy in patients with a high risk for fractures (mean femoral neck T score of −3.0 or less). A recently published meta-analysis assessing the nonvertebral antifracture efficacy corresponding to the …

medicine.medical_specialtyOsteoporosisUrologyIbandronic acidThoracic VertebraeBone DensityMedicineHumansIn patientDosingIbandronic AcidOsteoporosis PostmenopausalFemoral neckBone mineralLumbar VertebraeBone Density Conservation AgentsDiphosphonatesbusiness.industryInjection therapyGeneral Medicinemedicine.diseaseSurgerymedicine.anatomical_structureTolerabilityCervical Vertebraebusinessmedicine.drugWomen's health (London, England)
researchProduct

Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review

2011

In this paper we describe the results of a systematic search of the literature on conversion ratios during opioid switching. This is part of a project of the European Palliative Care Research Collaboration to update the European Association for Palliative Care recommendations for the use of opioid analgesics in the treatment of cancer pain. Studies were eligible for inclusion if they involved adult patients with chronic cancer pain, contained data on opioid conversion ratios, were prospective and were written in English. Thirty-one studies were identified and included. The majority of the studies had methodological flaws and were not designed to explore or demonstrate equianalgesic dose da…

medicine.medical_specialtyPalliative careMEDLINEPainDrug Administration ScheduleFentanylNeoplasmsmedicineHumansDrug Dosage CalculationsDosingIntensive care medicinePain MeasurementRandomized Controlled Trials as TopicDose-Response Relationship Drugbusiness.industryGeneral MedicineEquianalgesicAnalgesics OpioidEuropeAnesthesiology and Pain MedicineOpioidAnesthesiaPractice Guidelines as TopicCancer painbusinessmedicine.drugBuprenorphinePalliative Medicine
researchProduct

Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.

2016

Abstract Background Hereditary angioedema (HAE) is a rare disease characterized by C1-esterase inhibitor (C1-INH) deficiency, resulting in periodic attacks of acute edema, which can be life-threatening if they occur in the upper airway. No head-to-head comparisons of different treatment options for acute HAE attacks are available. Because immediate symptom relief is critical for potentially life-threatening laryngeal attacks, it is important to determine the treatment option that provides optimal treatment response. Objective Review and compare data from clinical studies that evaluated the efficacy and safety of treatments for laryngeal HAE attacks. Methods We conducted an indirect comparis…

medicine.medical_specialtyPathologyefficacyLaryngeal Diseases03 medical and health sciencesEcallantidechemistry.chemical_compound0302 clinical medicineSymptom reliefIcatibantInternal medicinemedicineHumans030212 general & internal medicineProspective cohort studyC1 esterase inhibitor deficiencybusiness.industryHAEAngioedemas Hereditarymedicine.diseaselaryngealTreatment Outcome030228 respiratory systemchemistryHereditary angioedemaEmergency MedicineC1-INHre-dosingbusinessAirwayComplement C1 Inhibitor Proteinmedicine.drugRare diseaseThe Journal of emergency medicine
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

Determinants of adherence to osteoporosis treatment in clinical practice.

2006

Introduction: Poor adherence to prescribed treatments is widespread in clinical practice and this can lead to potentially life-threatening events. This problem is apparently very common for osteoporosis treatment but the causes of discontinuation and low compliance are complex and poorly defined. Methods: Global adherence to osteoporosis treatment was specifically addressed in a nation-wide survey carried out in 9851 postmenopausal women referred to 141 Italian centres for osteoporosis management for a follow-up assessment, at least one year after having been prescribed a treatment with one of the following drugs: calcium±vitamin D supplements alone (CaVitD), hormone replacement therapy (HR…

medicine.medical_specialtySettore MED/09 - Medicina InternaHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisosteoporosis; Determinants; Treatment adherence; Treatmentadherence; compliance; osteoporosis; persistence; treatmentInternal medicinemedicineTreatment adherenceHumansRaloxifeneDosingVitamin DDeterminantsOsteoporosis PostmenopausalAgedAdherence Compliance Osteoporosis Persistence TreatmentBone Density Conservation Agentsbusiness.industryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseosteoporosisRheumatologyDiscontinuationMenopauseTreatmentItalyOrthopedic surgeryPhysical therapyPatient ComplianceCalciumFemalebusinessmedicine.drugOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
researchProduct

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-i…

2022

Summary Background Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to assess optimised vancomycin dosing. We compared the efficacy of an optimised regimen to a standard regimen in infants with late onset sepsis that was known or suspected to be caused by Gram-positive microorganisms. Methods NeoVanc was an open-label, multicentre, phase 2b, parallel-group, randomised, non-inferiority trial comparing the efficacy and toxicity of an optimised regimen of vancomycin to a standard regimen in infants aged …

medicine.medical_specialtyTime FactorsPopulationEquivalence Trials as TopicLoading doseArticlelaw.inventionGram-positiveRandomized controlled triallawVancomycinIntensive careInternal medicineIntensive Care Units NeonatalSepsisDevelopmental and Educational PsychologyClinical endpointMedicineHumansDosingeducationInfusions Intravenouseducation.field_of_studybusiness.industryInfant NewbornInfantdosingUnited KingdomAnti-Bacterial AgentsEuropeRegimenTreatment OutcomeSpainRelative riskPediatrics Perinatology and Child Healthsepsibusiness
researchProduct